Francisco Olmo

Dr. Francisco Olmo

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Amanda Fortes FranciscoAmanda Fortes Francisco
Amanda Fortes Francisco
SJShiromani Jayawardhana
Shiromani Jayawardhana
FOFrancisco Olmo
Francisco Olmo
MLMichael D. Lewis
Michael D. Lewis
SWShane R. Wilkinson
Shane R. Wilkinson
JKJohn Kelly
John Kelly
The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public health problem throughout Latin America. Current therapeutic options are characterised by limited efficacy, long treatment regimens and frequent toxic side-effects. Advances in this area have been compromised by gaps in our knowledge of disease pathogenesis, parasite biology and drug activity. Nevertheless, several factors have come together to create a more optimistic scenario. Drug-based research has become more systematic, with increased collaborations between the academic and commercial sectors, often within the framework of not-for-profit consortia. High-throughput screening of compound libraries is being widely applied, and new technical advances are helping to streamline the drug development pipeline. In addition, drug repurposing and optimisation of current treatment regimens, informed by laboratory research, are providing a basis for new clinical trials. Here, we will provide an overview of the current status of Chagas disease drug development, highlight those areas where progress can be expected, and describe how fundamental research is helping to underpin the process.

13 November 2023 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
SJShiromani Jayawardhana
Shiromani Jayawardhana
AWAlexander I. Ward
Alexander I. Ward
AFAmanda F. Francisco
Amanda F. Francisco
MLMichael D. Lewis
Michael D. Lewis
MTMartin C. Taylor
Martin C. Taylor
FOFrancisco Olmo
Francisco Olmo
Benznidazole is the front-line drug used to treat infections with Trypanosoma cruzi, the causative agent of Chagas disease. However, for reasons that are unknown, treatment failures are common. When we examined parasites that survived benznidazole treatment in mice using highly sensitive in vivo and ex vivo bioluminescence imaging, we found that recrudescence is not due to persistence of parasites in a specific organ or tissue that preferentially protects them from drug activity. Surviving parasites are widely distributed and located in host cells where the vast majority contained only one or two amastigotes. Therefore, infection relapse does not arise from a small number of intact large nests. Rather, persisters are either survivors of intracellular populations where co-located parasites have been killed, or amastigotes in single/low-level infected cells exist in a state where they are less susceptible to benznidazole. To better assess the nature of parasite persisters, we exposed infected mammalian cell monolayers to a benznidazole regimen that reduces the intracellular amastigote population to <1% of the pre-treatment level. Of host cells that remained infected, as with the situation in vivo, the vast majority contained only one or two surviving intracellular amastigotes. Analysis, based on non-incorporation of the thymidine analogue EdU, revealed these surviving parasites to be in a transient non-replicative state. Furthermore, treatment with benznidazole led to widespread parasite DNA damage. When the small number of parasites which survive in mice after non-curative treatment were assessed using EdU labelling, this revealed that these persisters were also initially non-replicative. A possible explanation could be that triggering of the T. cruzi DNA damage response pathway by the activity of benznidazole metabolites results in exit from the cell cycle as parasites attempt DNA repair, and that metabolic changes associated with non-proliferation act to reduce drug susceptibility. Alternatively, a small percentage of the parasite population may pre-exist in this non-replicative state prior to treatment.

23 August 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
AKArchie A. Khan
Archie A. Khan
HLHarry C. Langston
Harry C. Langston
FCFernanda C. Costa
Fernanda C. Costa
FOFrancisco Olmo
Francisco Olmo
MTMartin Taylor
Martin Taylor
MLMichael D. Lewis
Michael D. Lewis
Digestive Chagas disease (DCD) is an enteric neuropathy caused byTrypanosoma cruziinfection. The mechanism of pathogenesis is poorly understood and the lack of a robust, predictive animal model has held back research. We screened a series of mouse models using gastrointestinal tracer assays andin vivoinfection imaging systems to discover a subset exhibiting chronic digestive transit dysfunction and significant retention of faeces in both sated and fasted conditions. The colon was a specific site of both tissue parasite persistence, delayed transit and dramatic loss of myenteric neurons as revealed by whole-mount immunofluorescence analysis. DCD mice therefore recapitulated key clinical manifestations of human disease. We also exploited dual reporter transgenic parasites to home in on locations of rare chronic infection foci in the colon byex vivobioluminescence imaging and then used fluorescence imaging in tissue microdomains to reveal co-localisation of infection and enteric nervous system lesions. This indicates that long-termT.cruzi-host interactions in the colon drive DCD pathogenesis, suggesting that the efficacy of anti-parasitic chemotherapy against chronic disease progression warrants further pre-clinical investigation.

1 November 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
IBIván Beltran-Hortelano
Iván Beltran-Hortelano
RARichard L. Atherton
Richard L. Atherton
MRMercedes Rubio-Hernández
Mercedes Rubio-Hernández
JSJulen Sanz-Serrano
Julen Sanz-Serrano
VAVerónica Alcolea
Verónica Alcolea
FOFrancisco Olmo
Francisco Olmo

1 December 2018 in Molecular and Biochemical Parasitology
Verified
Journal Article
Open access
FOFrancisco Olmo
Francisco Olmo
FCFernanda C. Costa
Fernanda C. Costa
GMGurdip Singh Mann
Gurdip Singh Mann
MTMartin Taylor
Martin Taylor
JKJohn Kelly
John Kelly
The limited flexibility and time-consuming nature of the genetic manipulation procedures applicable to Trypanosoma cruzi continue to restrict the functional dissection of this parasite. We hypothesised that transformation efficiency could be enhanced if electroporation was timed to coincide with DNA replication. To test this, we generated epimastigote cultures enriched at the G1/S boundary using hydroxyurea-induced cell-cycle synchronisation, and then electroporated parasites at various time points after release from the cell-cycle block. We found a significant increase in transformation efficiency, with both episomal and integrative constructs, when cultures were electroporated 1 h after hydroxyurea removal. It was possible to generate genetically modified populations in less than 2 weeks, compared to the normal 4-6 weeks, with a 5 to 8-fold increase in the number of stably transformed clones. This straightforward optimisation step can be widely applied and should help streamline functional studies in T. cruzi.

Verified
Journal Article
Open access
PDF file
CSCauê Benito Scarim
Cauê Benito Scarim
FOFrancisco Olmo
Francisco Olmo
EFElizabeth Igne Ferreira
Elizabeth Igne Ferreira
CCChung Man Chin
Chung Man Chin
JKJohn Kelly
John Kelly
Amanda Fortes FranciscoAmanda Fortes Francisco
Amanda Fortes Francisco
Hydroxymethylnitrofurazone (NFOH) is a therapeutic candidate for Chagas disease (CD). It has negligible hepatotoxicity in a murine model compared to the front-line drug benznidazole (BZN). Here, using Trypanosoma cruzi strains that express bioluminescent and/or fluorescent reporter proteins, we further investigated the in vitro and in vivo activity of NFOH to define whether the compound is trypanocidal or trypanostatic. The in vitro activity was assessed by exploiting the fluorescent reporter strain using wash-out assays and real-time microscopy. For animal experimentation, BALB/c mice were inoculated with the bioluminescent reporter strain and assessed by highly sensitive in vivo and ex vivo imaging. Cyclophosphamide treatment was used to promote parasite relapse in the chronic stage of infection. Our data show that NFOH acts by a trypanostatic mechanism, and that it is more active than BZN in vitro against the infectious trypomastigote form of Trypanosoma cruzi. We also found that it is more effective at curing experimental infections in the chronic stage, compared with the acute stage, a feature that it shares with BZN. Therefore, given its reduced toxicity, enhanced anti-trypomastigote activity, and curative properties, NFOH can be considered as a potential therapeutic option for Chagas disease, perhaps in combination with other trypanocidal agents.